New treatment for anti-NMDAR autoimmune encephalitis reports Charité – Universitätsmedizin Berlin
February 2, 2017
One of the one of the largest university hospitals in Europe, Charite’, recorded significant progress in treating anti-NMDAR, including in patients who did not previously respond to treatment. Anti-NMDA receptor encephalitis is an inflammatory disease that affects the central nervous system. It is a rare autoimmune disease that results in the body producing antibodies against the NMDA receptor, a protein that plays an important role in signal transduction in the brain. Using a new treatment regimen, researchers have recorded significant progress in treating the disease, including in patients who did not previously respond to treatment. Visit Science Daily to read the full report.
